Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Polygenic risk scores stratify breast cancer risk among women with benign breast disease
Sherman, Mark E. , Winham, Stacey J. , Vierkant, Robert A. , McCauley, Bryan M. , Scott, Christopher G. , Schrup, Sarah E. , Gaudet, Mia M. , Troester, Melissa A. , Pruthi, Sandhya , Bolla, Manjeet K. , Wang, Qin , Dennis, Joe, Chang‐Claude, Jenny , Obi, Nadia, Aronson, Kristan J. , García‐Closas, Montserrat , Yang, Xiaohong R. , Pharoah, Paul D.P., Easton, Douglas F., Vachon, Celine M, Schrup, Sarah, Radisky, Derek C. , Wang, Qin , Dennis, Joe , Michailidou, Kyriaki , Truong, Therese , Obi, Nadia , Aronson, Kristan J , García-Closas, Montserrat , Chanock, Stephen Jacob , Yang, Xiaohong R , Mavaddat, Nasim , Easton, Doug , Vachon, Celine M. , Winham, Stacey J , Vierkant, Robert A , Scott, Christopher , Gaudet, Mia M , Sherman, Mark E , Degnim, Amy C. , Couch, Fergus J. , Michailidou, Kyriaki , Guénel, Pascal , Truong, Thérèse , Murphy, Rachel A. , Ahearn, Thomas U. , Dunning, Alison M. , Easton, Douglas F.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 16, 2024 | Volume: 117 | Issue: 3 | Pages: 456-464

10.1093/jnci/djae255 | PMID 39412492 Get It

Abstract Background Most breast biopsies are diagnosed as benign breast disease, with 1.5- to 4-fold increased breast cancer risk. Apart from pathologic diagnoses of atypical hyperplasia, few factors aid in breast cancer risk assessment of these patients. We assessed whether a 313–single nucleotide variation (formerly single-nucleotide polymorphism) polygenic risk score stratifies risk of benign breast disease patients. Methods We pooled data from 5 Breast Cancer Association Consortium case-control studies (mean age = 59.9 years), including 6706 participants with breast cancer and 8488 participants without breast cancer. Using logistic regression, we estimated breast cancer risk associations by self-reported benign breast disease history and strata of polygenic risk score, with median polygenic risk score category among women without benign breast disease as the referent. We assessed interactions and mediation of benign breast disease and polygenic risk score with breast cancer risk. Results Benign breast disease history was associated with increased breast cancer risk (odds ratio [OR] = 1.48, 95% confidence interval [CI] = 1.37 to 1.60; P < .001). Polygenic risk score increased breast cancer risk, irrespective of benign breast disease history (Pinteraction = .48), with minimal evidence of mediation of either factor by the other. Women with benign breast disease and polygenic risk score in the highest tertile had more than twofold increased odds of breast cancer (OR = 2.73, 95% CI = 2.41 to 3.09), and those with benign breast disease and polygenic risk score in the lowest tertile experienced reduced breast cancer risk (OR = 0.79, 95% CI = 0.70 to 0.91) compared with the referent group. Women with benign breast disease and polygenic risk score in the highest decile had a 3.7-fold increase (95% CI = 3.00 to 4.61) compared with those with median polygenic risk score without benign breast disease. Conclusion Breast cancer risks are elevated among women with benign breast disease and increase progressively with polygenic risk score, suggesting that optimal combinations of these factors may improve risk stratification.
Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica
Vorasoot, Nisa , Abdulrahman, Yahya, Mateen, Farrah J. , Fryer, James P., Redenbaugh, Vyanka , Sagen, Jessica, Jenkins, Sarah M. , Gorsh, Amy P., Chen, John J. , Ζεκερίδου, Αναστασία , Mills, John R. , Pittock, Sean J. , Pittock, S J , Abdulrahman, Yahya J, Mateen, Farrah , Sagen, Jessica A., Zekeridou, Anastasia , McKeon, Andrew , Flanagan, E P , Chen, John J , Vorasoot, Nisa , Musubire, Abdu Kisekka , McKeon, Andrew , Flanagan, Eoin P.

Mayo Clinic

Annals of Clinical and Translational Neurology | October 15, 2024 | Volume: 11 | Issue: 11 | Pages: 2855-2865

10.1002/acn3.52178 | PMID 39406378 Get It

AbstractObjectiveThis study aimed to evaluate the diagnostic accuracy of dried blood spot (DBS) compared with conventional serum Aquaporin‐4‐IgG (AQP4‐IgG) testing.MethodsProspective multicenter diagnostic study was conducted between April 2018 and October 2023 across medical centers in the United States, Uganda, and the Republic of Guinea. Neuromyelitis optica spectrum disorder (NMOSD) patients and controls collected blood on filter paper cards along with concurrent serum samples. These samples underwent analysis using flow cytometric live‐cell‐based assays (CBA) and enzyme‐linked immunosorbent assay (ELISA) to determine AQP4 serostatus. The accuracy of AQP4‐IgG detection between DBS and serum (gold standard) was compared.ResultsAmong 150 participants (47 cases, 103 controls), there was a strong correlation between DBS and serum samples (Spearman's correlation coefficient of 0.82). The AUC was 0.97 (95% CI: 0.92–0.99). AQP4‐IgG detection through DBS showed 87.0% sensitivity (95% CI: 0.74–0.95) and 100% specificity (95% CI: 0.96–1.00) using CBA, and 65.2% sensitivity (95% CI: 0.43–0.84) and 95.2% specificity (95% CI: 0.76–0.99) using ELISA. Serum ELISA demonstrated 69.6% sensitivity (95% CI: 0.47–0.87) and 98.4% specificity (95% CI: 0.91–0.99). The stability of DBS in detecting AQP4‐IgG persisted over 24 months for most cases.InterpretationThe DBS represents a viable alternative for detecting AQP4‐IgG in resource‐limited settings to diagnose NMOSD, offering high sensitivity and specificity comparable to serum testing. Moreover, DBS has low shipping costs, is easy to administer, and is suitable for point‐of‐care testing.
Closing the gap between biology and classification in splenic B‐cell lymphomas
Blombery, Piers , Ferry, Judith A. , Ondrejka, Sarah L. , Seymour, John F. , Zamò, Alberto , Tzankov, Alexandar , Zamò, Alberto , Tzankov, Alexandar , Jong, Daphne de , Hsi, Eric D.

Mayo Clinic

Histopathology | October 15, 2024 | Volume: 86 | Issue: 1 | Pages: 69-78

10.1111/his.15323 | PMID 39403047 Get It

The mature splenic B‐cell lymphomas are an enigmatic group of lymphoid neoplasms that have long caused significant difficulty for the practicing pathologist due to overlapping diagnostic features among entities and the decreasing availability of splenic tissue for assessment. While some entities have highly characteristic and specific clinicopathological features (e.g. hairy cell leukaemia), others are substantially more difficult to recognise (e.g. splenic diffuse red pulp lymphoma). At the same time, classification systems have been evolving, resulting in multiple changes to the boundaries among these entities and even the existence of some entities in their own right. Moreover, unbiased multi‐omic interrogation (whole genome/transcriptome sequencing, methylome) of the splenic B‐cell lymphomas over the past decade has given us significant insights into the underling biology of these neoplasms. We present a clinicopathological perspective on the historical, current and future state of the diagnosis and classification of splenic B‐cell lymphomas integrating multi‐omic data and highlighting areas of focus for the field in order to continue to strive to improve patient outcomes through accurate diagnosis.
DICER1 -Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies
Schultz, Kris Ann P. , Nelson, Alexander T. , Mallinger, Paige, Harris, Anne K. , Kamihara, Junne , Baldinger, Shari , Chen, Kenneth , Pond, Dinel , Hatton, Jessica N. , Dybvik, Anna, Perrino, Melissa R. , Ami, Tal Ben , Su, Yan , Duan, Cuihai , Watson, David , Field, Amanda L., Carr, Ann G. , Schneider, Dominik T. , Schoettler, Peter , Dehner, Louis P. , Mallinger, Paige H R , Chen, Kenneth S , Dybvik, Anna G , Mitchell, Sarah G , Perrino, Melissa R , Ben-Ami, Tal , Kachanov, Denis , Su, Yan , Duan, Chao , Olson, Damon R , Watson, Dave , Field, Amanda L , Harney, Laura A , Garrity Carr, Ann , Frazier, A Lindsay , Schneider, Dominik T , Wilson, David B , MacFarland, Suzanne P , Schoettler, Peter J , Bauer, Andrew J , Dehner, Louis P , Hill, Dana Ashley , Stewart, Douglas R , Messinger, Yoav H , Harris, Anne K , Olson, Damon R. , Wilson, David B. , Messinger, Yoav H.

Mayo Clinic

Clinical Cancer Research | October 14, 2024 | Volume: 30 | Issue: 24 | Pages: 5681-5692

10.1158/1078-0432.ccr-24-1532 | PMID 39400264 Get It

Abstract Purpose: DICER1-related tumor predisposition increases risk for a spectrum of benign and malignant tumors. In 2018, the International Pleuropulmonary Blastoma (PPB)/DICER1 Registry published guidelines for testing- and imaging-based surveillance of individuals with a known or suspected germline DICER1 pathogenic or likely pathogenic (P/LP) variant. One of the goals of the Registry is to continue to refine these guidelines as additional data become available. Experimental Design: Individuals were enrolled in the International PPB/DICER1 Registry, the International Ovarian and Testicular Stromal Tumor Registry, and/or the NCI Natural History of DICER1 Syndrome study. Results: Review of participant records identified 713 participants with a germline DICER1 P/LP variant from 38 countries. To date, 5 cases of type I and 29 cases of type Ir PPB have been diagnosed by surveillance in enrolled individuals. One hundred and three individuals with a germline P/LP variant developed a primary ovarian Sertoli–Leydig cell tumor at a median age of 14 years (range: 11 months–66 years); 13% were diagnosed before 8 years of age, the current age of onset of pelvic surveillance. Additionally, 4% of Sertoli–Leydig cell tumors were diagnosed before 4 years of age. Conclusions: Ongoing data collection highlights the role of lung surveillance in the early detection of PPB and suggests that imaging-based detection and early resection may decrease the risk of advanced PPB. DICER1-related ovarian tumors were detected before 8 years of age, prompting the Registry to recommend earlier initiation of ovarian surveillance with pelvic ultrasound beginning at the time of detection of a germline DICER1 P/LP variant.
Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival
Ajufo, Helen, Harrison, Claire , Palmer, Jeanne , Buckley, Sarah , Roman‐Torres, Karisse, Rampal, Raajit K. , Bewersdorf, Jan Philipp , Palandri, Francesca , Mascarenhas, John , Gerds, Aaron T. , Kiladjian, Jean‐Jacques , Derkach, Andriy

Mayo Clinic

European Journal of Haematology | October 14, 2024 | Volume: 114 | Issue: 2 | Pages: 238-247

10.1111/ejh.14321 | PMID 39400386 Get It

ABSTRACTSpleen volume reduction (SVR) is a key endpoint in inhibitors of Janus kinase (JAK) inhibitor studies. Retrospective analyses have demonstrated an association between SVR and improved overall survival (OS) among patients treated with ruxolitinib with a platelet count > 100 × 109/L. Whether this association occurs in patients with thrombocytopenia is unclear. Pacritinib, a JAK2/IRAK1/ACVR1 inhibitor, demonstrated improved SVR versus best available therapy (BAT [best available therapy]; including ruxolitinib) in patients with myelofibrosis and platelet counts ≤ 100 × 109/L in the PERSIST‐2 study. Patients on study at the start of the 12‐week SVR window on pacritinib 200 mg twice daily or BAT were included. OS was evaluated among SVR responders versus non‐responders using different SVR thresholds (≥ 35%, ≥ 20%, ≥ 10%, and > 0%). Among patients on pacritinib (n = 89), SVR ≥ 10% demonstrated the greatest separation in OS curves between responders and non‐responders (HR, 0.00; 95% CI, 0.00–0.14; p < 0.01), though SVR ≥ 0% and SVR ≥ 20% were also associated with improved OS. No SVR threshold conferred OS benefit on BAT (n = 84), including ruxolitinib (n = 39). In patients with myelofibrosis and platelets ≤ 100 × 109/L, achieving SVR on pacritinib, but not BAT (including ruxolitinib), was associated with significant OS benefit, suggesting that pacritinib may offer a unique survival advantage in patients with myelofibrosis and thrombocytopenia who achieve any SVR. Trial Registration: ClinicalTrials.gov number: NCT02055781
Artificial Intelligence–Based Assessment of Preoperative Body Composition is Associated With Early Complications After Radical Cystectomy
Sharma, Vidit , Fadel, Anthony , Tollefson, Matthew K. , Blezek, Daniel J. , Frank, Igor, Thapa, Prabin , Tarrell, Robert F., Viers, Lyndsay D., Potretzke, Aaron M. , Hartman, Robert P. , Boorjian, Stephen A. , Tarrell, Robert, Viers, Boyd R. , Fadel, Anthony , Psutka, Sarah P.

Mayo Clinic

Journal of Urology | October 11, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ju.0000000000004292 | PMID 39392812 Get It

Return to Work in Breast Cancer Patients With and Without Pre-Diagnosis Psychological Distress: A Prospective Cohort Study
Pai, Tanmayi , McLaughlin, Sarah A., Pruthi, Sandhya , Klassen, Christine L. , Cornell, Lauren , Li, Zhuo , Cornell, Lauren F

Mayo Clinic

No container title available | October 11, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4266430/v1 Get It

Abstract Purpose Many women are employed at the time of breast cancer (BC) diagnosis. Pre-diagnosis psychological distress is prevalent among early-stage BC patients. We prospectively evaluated return to work (RTW) in BC patients with and without reported pre-diagnosis psychological distress over a 15-month period to determine if such distress affects workforce participation and mental health status after curative treatment. Methods 188 patients with newly diagnosed stage 0-III BC and working 35-plus hours/week participated at Mayo Clinic in Minnesota and Florida. Patients received an email survey at diagnosis and 3 and 15 months later. Incidence of severe psychological distress (SPD) per the Kessler Psychological Distress Scale (K6, score ≥ 13) was assessed at each timepoint. Results 77/188 survey respondents (41%) reported pre-diagnosis psychological distress, with 23.5% noting job-related stress. 59/188 patients (31%) had SPD at diagnosis, with similar incidence in the group that had pre-diagnosis distress (+ stress) and the non-stressed group (no-stress). The sample was highly educated and well salaried. The + stress group worked more hours on average at diagnosis (41.3 vs. 39.3 hours, p = 0.034). At 3 months, 83/141 respondents (60.1%) reported taking time off work after diagnosis, with 46.6% returning within 2 weeks and 42.5% requiring > 4 weeks’ break. More + stress patients reported RTW to maintain health insurance (13/56 vs. 6/85, p = 0.006), although this difference resolved by 15 months. SPD rates decreased over time but affected 17/104 respondents (16.3%) at 15 months. Conclusion Job-related stress is a primary driver of pre-diagnosis psychological distress. Three months after BC diagnosis, many women with pre-diagnosis psychological distress were motivated to RTW to keep employer-linked health insurance. SPD is prominent in BC patients; while SPD declined over time, it did not resolve completely.
Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice
Dizman, Nazlı , Bakouny, Ziad , Haykal, Tarek , Riaño, Ivy , Desai, Aakash , Butt, Ayesha , Basu, Arnab , Zhao, Dan , Saad, Eddy , Saliby, Renée Maria , Gosain, Rohit , Gosain, Rahul , Ardeshir, Fatemeh , Matt-Amaral, Laurie , Arnaoutakis, Konstantinos , Bekaii‐Saab, Tanios , Marshall, Ariela L. , Murphy, Martina, Lopes, Gilberto , Lee, Alfred Ian , Deng, Lei , Matt-Amaral, Laurie , Arnaoutakis, Konstantinos , Bekaii-Saab, Tanios S , Manochakian, Rami , Marshall, Ariela , Forde, Patrick , Subbiah, Vivek , Chavez-MacGregor, Mariana , Owonikoko, Taofeek Kunle , Lopes, Gilberto , Aggarwal, Charu , Lee, Alfred I , Choueiri, Toni K , Desai, Aakash P , Bakouny, Ziad , Basu, Arnab , Butt, Ayesha , Zhao, Dan , Saad, Eddy , Deng, Lei , Manochakian, Rami , Forde, Patrick M. , Subbiah, Vivek , Chávez‐MacGregor, Mariana , Aggarwal, Charu , Choueiri, Toni K.

Mayo Clinic

JCO Oncology Practice | October 7, 2024 | Volume: 21 | Issue: 3 | Pages: 292-299

10.1200/op-24-00565 | PMID 39374449 Get It

PURPOSE International medical graduates (IMGs) are an essential component of the oncology workforce in the United States, comprising a third of all practicing oncologists and almost half of hematology/oncology fellows. In this article, we discuss the contributions of IMGs in the US oncology workforce, review unique challenges faced by IMGs, and propose potential solutions to overcome these challenges. METHODS ASCO's IMG Community of Practice was established with the mission to connect, mentor, guide, raise awareness, and overcome the challenges unique to IMGs interested in pursuing medical oncology in the United States. The content of this article is based on discussions at the IMG Community of Practice meetings at ASCO's 2023 and 2024 Annual Meetings. RESULTS IMGs bring an inherent diversity of thought and experience to the oncology workforce. They provide high-quality, culture- and language-concordant care to a diverse population of patients with cancer. However, IMGs in oncology face significant hardships throughout their careers, including visa-related restrictions, psychosocial and cultural struggles, as well as differential treatment while applying for residency and fellowship training, and early career positions. Greater awareness of these challenges among the members of the hematology/oncology community, along with institutional and individual efforts to support IMGs, is warranted. CONCLUSION We encourage oncology professionals and institutions to join our efforts in recognizing the unique paths of IMGs and providing support and advocacy to maximize the potential of IMGs in the US oncology workforce.
Axonal damage and inflammation response are biological correlates of decline in small-world values: a cohort study in autosomal dominant Alzheimer’s disease
Vermunt, Lisa , Dicks, Ellen , Leeuw, Diederick M de , Berman, Sarah , Cash, David M. , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Day, Gregory S. , Ewers, Michael , Farlow, Martin R. , Fox, Nick C. , Ghetti, Bernardino , Graff‐Radford, Neill R., Hassenstab, Jason , Laske, Christoph , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Morris, John C. , Perrin, Richard J. , Preische, Oliver, Xiong, Chengjie , Fagan, Anne M. , de Leeuw, Diederick M , Cash, David M , Chhatwal, Jasmeer , Cruchaga, Carlos , Ewers, Michael , Kuhle, Jens , Masters, Colin L , Morris, John C , Teunissen, Charlotte E , Bateman, Randall J , Gordon, Brian A , Tijms, Betty M , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Ghetti, Bernardino F , Berman, Sarah , Sutphen, Courtney L. , Allegri, Ricardo , Graff‐Radford, Neill R. , Jucker, Mathias , Karch, Celeste M. , Kühle, Jens , McDade, Eric , Schofield, Peter R. , Suárez‐Calvet, Marc , Xiong, Chengjie , Scheltens, Philip , Teunissen, Charlotte E. , Visser, Pieter Jelle , Bateman, Randall J. , Benzinger, Tammie L.S. , Gordon, Brian A. , Tijms, Betty M.

Mayo Clinic

Brain Communications | October 7, 2024 | Volume: 6 | Issue: 5 | Pages: No page available

10.1093/braincomms/fcae357 | PMID 39440304 Get It

Abstract The grey matter of the brain develops and declines in coordinated patterns during the lifespan. Such covariation patterns of grey matter structure can be quantified as grey matter networks, which can be measured with magnetic resonance imaging. In Alzheimer’s disease, the global organization of grey matter networks becomes more random, which is captured by a decline in the small-world coefficient. Such decline in the small-world value has been robustly associated with cognitive decline across clinical stages of Alzheimer’s disease. The biological mechanisms causing this decline in small-world values remain unknown. Cerebrospinal fluid (CSF) protein biomarkers are available for studying diverse pathological mechanisms in humans and can provide insight into decline. We investigated the relationships between 10 CSF proteins and small-world coefficient in mutation carriers (N = 219) and non-carriers (N = 136) of the Dominantly Inherited Alzheimer Network Observational study. Abnormalities in Amyloid beta, Tau, synaptic (Synaptosome associated protein-25, Neurogranin) and neuronal calcium-sensor protein (Visinin-like protein-1) preceded loss of small-world coefficient by several years, while increased levels in CSF markers for inflammation (Chitinase-3-like protein 1) and axonal injury (Neurofilament light) co-occurred with decreasing small-world values. This suggests that axonal loss and inflammation play a role in structural grey matter network changes.
8219 Biochemical Disease Severity Score For Hypercortisolism Can Predict Adrenal Insufficiency After Adrenalectomy For Mild Autonomous Cortisol Secretion
Salama, Bahaa , Dackiw, Alan P.B., Nwariaku, Fiemu E., Islam, Ana , Mehta, Ankeeta , Mirfakhraee, Sasan , McKenzie, Travis J. , Foster, Trenton R. , Lyden, Melanie L. , Dy, Benzon M. , Hamidi, Oksana , Dogra, Prerna , Oltmann, Sarah Catherine , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.124 Get It

Abstract Disclosure: O. Hamidi: Advisory Board Member; Self; Corcept, Neurocrine Biosciences, Amryt Pharma, Recordati Rare Diseases, Lantheus, Xeris. B.H. Salama: None. P. Dogra: None. A.P. Dackiw: None. F. Nwariaku: None. A. Islam: None. A. Mehta: None. S.C. Oltmann: None. S. Mirfakhraee: None. T. McKenzie: None. T.R. Foster: None. M. Lyden: None. B.M. Dy: None. I. Bancos: None. Introduction: Patients with mild autonomous cortisol secretion (MACS) are at risk for adrenal insufficiency (AI) after unilateral adrenalectomy. We aimed to determine the prevalence, predictors, and duration of AI after unilateral adrenalectomy for MACS, and to compare baseline and peak cortisol post cosyntropin stimulation test (CST) in diagnosing AI. Methods: We conducted a dual-center retrospective cohort study of patients with MACS who underwent unilateral adrenalectomy and were evaluated with postoperative cosyntropin stimulation test (CST). AI was diagnosed when postoperative morning cortisol was &lt;10μg/dL and/or CST peak cortisol was &lt;18μg/dL. Baseline and CST peak cortisol levels were considered concordant when both met corresponding cut-offs. Biochemical (BSS) and clinical (CSS) severity scores for hypercortisolism were calculated. Results: In 100 adults with MACS (77% women, median age 56 years, interquartile range [IQR] 48-63), median adenoma size was 2.8 cm (IQR, 2.2-3.7), and 25 (25%) had bilateral nodules. Median BSS was 3 (IQR, 2-5) and median CSS was 4 (IQR, 2-8). After adrenalectomy, AI was diagnosed in 56 (56%) patients. AI was associated with higher BSS, larger tumor size, but not age, sex, BMI, tumor laterality. Baseline and CST peak cortisol levels were concordant in 76% of cases. In 14% of cases morning cortisol was &lt;10μg/dL but CST peak cortisol was ≥18μg/dL, and in 10% of cases morning cortisol was ≥10μg/dL, but CST peak cortisol was &lt;18μg/dL. On a multivariable analysis that included age, sex, BMI, BSS, laterality, and tumor size, only higher BSS (odd ratio [OR] = 1.6 per 1 point) was associated with postoperative baseline cortisol &lt;10μg/dL (P&lt;0.05 for all). Independent predictors of CST peak cortisol &lt;18μg/dL were BSS (OR 1.5 per 1 point) and unilateral adenoma (OR 3.7). During a median postoperative follow up of 13 months, 33 (59%) patients recovered from AI. Median time to recovery was 6.0 months, with AI recovery in 28% of patients by 2 months, 42% by 3 months, 53% by 6 months, and 64% by 12 months. Conclusions: Prevalence of postoperative AI in MACS was 56%. Only 76% of patients had concordant baseline and CST peak cortisol, with peak CST cortisol being more commonly abnormal in patients treated for unilateral MACS. Patients with larger adenomas and higher BSS were at higher risk for AI. Patients with MACS should be counseled about the risk and duration of AI after adrenalectomy. Presentation: 6/3/2024